

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Elazar Rabbani et al.
 Serial No. 08/978,632
 Filed: November 25, 1997
 Group Art Unit: 1635
 Examiner: Mary M. Schmidt



Title: NOVEL PROPERTY EFFECTING AND/OR PROPERTY EXHIBITING COMPOSITIONS FOR THERAPEUTIC AND DIAGNOSTIC USES

FILED BY FIRST CLASS MAIL

Honorable Commissioner of
 Patents and Trademarks
 Washington, D. C. 20231

Sir:

Transmitted herewith is An Amendment Under 37 C.F.R. §1.115 (In Response to The February 3, 1999 Office Action) in the above-identified patent application.

The fee* has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
Total	25	Minus	24	=1	X\$9.00	\$ 9.00
Indep	2	Minus	2	=0	X\$39.00	\$ 0.00
()	First Presentation of Multiple Dependent Claims				\$130.00	\$
	TOTAL ADDITIONAL FEE					\$39.00

*Small entity status was previously established in this application and is still applicable.

() Charge Deposit Account No. 05-1135 in the amount of \$ _____

() A check in the amount of \$ _____ is attached.

(X) The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 05-1135 any filing fees under 37 C.F.R. §1.16 for the presentation of extra claims and any patent application processing fees under 37 C.F.R. §1.17.

Copies are being provided in triplicate.

Also enclosed: Request for An Extension of Time (3 Months), Declaration Under 37 C.F.R. §1.821(g), Second Communication Directed To Notice To Comply With Sequence Rules, Second Amendment In Connection With Notice to Comply With Requirements For Patent Application Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures Under 37 C.F.R. §§1.821-1.825, a computer readable form (CRF) of the substitute Sequence Listing and a substitute initial paper copy of the substitute sequence listing.

August 3, 1999

Date

Respectfully submitted,

Ronald C. Fedus

Registration No. 32,567

Attorney for Applicant(s)

ENZO THERAPEUTICS, INC.

c/o Enzo Biochem, Inc.
 527 Madison Avenue (9th Fl.)
 New York, New York 10022
 Tel. (212) 583-0100

Attorney's Docket No.: Enz-53(C)


lc:\Transmittal\Amendment\ENZ26(C2).072399

FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as first class mail in an envelope addressed to:
 Commissioner of Patents & Trademarks Washington,
 D.C. 20231

Ronald C. Fedus
 Reg. No. 32,567

AUG 3 99
 Date



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#10/C
chk
8-20-99

Applicant(s): Rabbani et al.

Serial No.: 08/978,632

Filed: November 25, 1997

For: NOVEL PROPERTY EFFECTING AND/OR
PROPERTY EXHIBITING COMPOSITIONS)
FOR THERAPEUTIC AND DIAGNOSTIC
USES

Group Art Unit: 1635

Examiner: Mary M. Schmidt

527 Madison Avenue (9th Floor)
New York, New York 10022
August 3, 1999


FILED BY FIRST CLASS MAIL

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

AMENDMENT UNDER 37 C.F.R. §1.115
(IN RESPONSE TO THE FEBRUARY 3, 1999 OFFICE ACTION)

Dear Sirs:

In connection with their above-identified application, Applicants are submitting this Amendment Under 37 C.F.R. §1.115 in response to the Office Action mailed on February 3, 1999 in connection with the above-identified application. This Amendment is being accompanied by a Request For An Extension Of Time (3 months) and authorization for the small entity fee therefor. Accordingly, this Amendment is being timely filed.

FIRST CLASS CERTIFICATE	
I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as first class mail in an envelope addressed to: Commissioner of Patents & Trademarks Washington, D.C. 20231	
 Ronald C. Fedus Reg. No. 32,567	AUG 3 99 Date

Enz-53(C)

08/27/1999
1 FC:203